Search

Screening for Sickle Cell Retinopathy (SCR): Why we do wide-field imaging, OCT/OCT-A for SCR – Newcastle upon Tyne Hospitals NHS Foundation Trust

I have been working in ophthalmology for over five years as a photographer and research co-ordinator, and it is fascinating, rewarding, and interesting to learn all about the different diseases associated with the eye. One condition that has been a...

A closer look at the new wave of glaucoma surgery – radical or old school?

Glaucoma is a challenging condition to treat because the exact pathophysiology remains unclear and the only readily modifiable factor is the intraocular pressure (IOP). Additionally, most glaucoma patients are completely asymptomatic, yet are often subjected to lifelong medical therapy. The...

The eye without tears

The Art is long and Life is short. So goes the dispiriting tag in Latin and flung from day one and at regular intervals thereafter at idle medical students who, inevitably brainwashed, come by graduation to believe that the only...

Improved efficacy expected with second-generation microinvasive glaucoma surgery (MIGS) devices

Microinvasive surgical approaches to primary open-angle glaucoma (POAG) offer minimally traumatic options for effective intraocular pressure (IOP) reduction in appropriately selected glaucoma patients. Increases in laser trabeculoplasty rates and wider adoption of glaucoma drainage device filtration procedures, together with the...

In conversation with Andy Pyott

Discussing a detour into ophthalmology from zoology in 1988, experiences in Asia, sub-Saharan Africa and Europe and the National Treatment Centre – Highland, Baljean Dhillon interviews his newest guest on the Eye Views podcast, Andy Pyott. Take us back to...

Learnings and trends in the management of open-angle and angle-closure glaucoma

To be truly disruptive, newer technologies need to offer a quality of life benefit over medication to a broad population of glaucoma sufferers. Evidence and converging trends in medical and surgical management of glaucoma were explored in counterpoint discussions and...

Initiatives in macular service provision

A report from Monitor in October 2015 identifies good practices that will realise most of the potential productivity gain in elective care available to NHS hospitals. These include: stratifying patients by risk and creating low-complexity pathways for lower-risk patients (tailoring...

NICE drugs: an update on what’s good to go

Treatment options recommended by the National Institute for Health and Care Excellence (NICE) must be readily available for use in the NHS of England and Wales. This article provides an overview of recent guidance from NICE and summary advice issued...

Treatment of diabetic macular oedema

Diabetic macular oedema (DMO) is a common complication associated with diabetic retinopathy, and the most common cause of visual impairment in diabetes [1]. With predicted rising levels of diabetes (in England by 2025 the estimated population with diabetes will be...